Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent
Indications (Market Use Context)
This phenomenon is further illustrated by results from a randomized, open-label mechanistic trial in patients with T2DM, which demonstrated that lixisenatide, with a half-life of 2 4 hours, had a significantly greater effect than liraglutide in delaying in gastric emptying and curtailing postprandial glucose excursions following a standardized solid breakfast (156)
With guidance from doctors, you receive support during every step
Advanced understanding of monogenic inflammatory bowel disease
Bao Z, Kim J, Kwok C, Le Devedec F, Allen C
US$ 21.97
US$ 27.66
US$ 20.89
US$ 25.56
